"Cytokine storm", not only in COVID-19 patients. Mini-review
- PMID: 33007369
- PMCID: PMC7524442
- DOI: 10.1016/j.imlet.2020.09.007
"Cytokine storm", not only in COVID-19 patients. Mini-review
Abstract
Cytokine storm is a form of uncontrolled systemic inflammatory reaction activated by a variety of factors and leading to a harmful homeostatic process, even to patient's death. Triggers that start the reaction are infection, systemic diseases and rarely anaphylaxis. Cytokine storm is frequently mentioned in connection to medical interventions such as transplantation or administration of drugs. Presented mini-review would like to show current possibilities how to fight or even stop such a life-threatening, immune-mediated process in order to save lives, not only in COVID-19 patients. Early identification of rising state and multilevel course of treatment is imperative. The most widely used molecule for systemic treatment remains tocilizumab. Except for anti IL-6 treatment, contemporary research opens the possibilities for combination of pharmaceutical, non-pharmaceutical and adjunctive treatment in a successful fight with consequences of cytokine storm. Further work is needed to discover the exact signaling pathways that lead to cytokine storm and to determine how these effector molecules and/or combination of processes can help to resolve this frequently fatal episode of inflammation. It is a huge need for all scientists and clinicians to establish a physiological rational for new therapeutic targets that might lead to more personalized medicine approaches.
Keywords: Cytokine release syndrome; Cytokine storm; Treatment.
Copyright © 2020 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
The author declares no commercial or financial conflict of interest.
Figures
Similar articles
-
Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.Rev Recent Clin Trials. 2021;16(2):138-145. doi: 10.2174/1574887115666200917110954. Rev Recent Clin Trials. 2021. PMID: 32940187 Review.
-
Targeting Cytokine Storm to Manage Patients with COVID-19: A Mini-Review.Arch Med Res. 2020 Oct;51(7):608-612. doi: 10.1016/j.arcmed.2020.06.012. Epub 2020 Jun 19. Arch Med Res. 2020. PMID: 32682575 Free PMC article. Review.
-
Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy.Int J Biol Sci. 2022 Jan 1;18(2):459-472. doi: 10.7150/ijbs.59272. eCollection 2022. Int J Biol Sci. 2022. PMID: 35002503 Free PMC article. Review.
-
Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.J Med Virol. 2020 Nov;92(11):2516-2522. doi: 10.1002/jmv.26038. Epub 2020 Jun 9. J Med Virol. 2020. PMID: 32436994 Free PMC article.
-
Cytokines and COVID-19: friends or foes?Hum Vaccin Immunother. 2020 Oct 2;16(10):2363-2365. doi: 10.1080/21645515.2020.1799669. Epub 2020 Aug 25. Hum Vaccin Immunother. 2020. PMID: 32841579 Free PMC article.
Cited by
-
Influenza virus causes lung immunopathology through down-regulating PPARγ activity in macrophages.Front Immunol. 2022 Aug 25;13:958801. doi: 10.3389/fimmu.2022.958801. eCollection 2022. Front Immunol. 2022. PMID: 36091002 Free PMC article.
-
Neuronal and Cerebrovascular Complications in Coronavirus Disease 2019.Front Pharmacol. 2020 Nov 20;11:570031. doi: 10.3389/fphar.2020.570031. eCollection 2020. Front Pharmacol. 2020. PMID: 33613275 Free PMC article. Review.
-
Mechanisms Governing Anaphylaxis: Inflammatory Cells, Mediators, Endothelial Gap Junctions and Beyond.Int J Mol Sci. 2021 Jul 21;22(15):7785. doi: 10.3390/ijms22157785. Int J Mol Sci. 2021. PMID: 34360549 Free PMC article. Review.
-
Fostering experimental and computational synergy to modulate hyperinflammation.Trends Immunol. 2022 Jan;43(1):4-7. doi: 10.1016/j.it.2021.11.004. Epub 2021 Nov 26. Trends Immunol. 2022. PMID: 34844849 Free PMC article.
-
Vaping-associated illness: a reassessment.Int J Emerg Med. 2024 Sep 2;17(1):107. doi: 10.1186/s12245-024-00692-4. Int J Emerg Med. 2024. PMID: 39223452 Free PMC article.
References
-
- Kroschinsky F., Stölzel F., von Bonin S., Beutel G., Kochanek M., et al. Intensive Care in Hematological and Oncological Patients (iCHOP) Collaborative Group. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care. 2017;21(1):89. doi: 10.1186/s13054-017-1678-1. - DOI - PMC - PubMed
-
- Stratton K., Ford A., Rusch E., Wright Clayton E., editors. Adverse effects of vaccines: Evidence and causality. IOM (Institute of Medicine), The National Academies Press; Washington: 2012. - PubMed
-
- Chatenoud L., Ferran C., Reuter A., Legendre C., Gevaert Y., et al. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected] N Engl J Med. 1989;320:1420–1421. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical